Insider · CIK 0002048634
Christoph Brackmann
cfoofficer
Files at NVCR (NovoCure Ltd). First filing Jul 30, 2025, latest Mar 5, 2026.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
1 / 1
$232k bought, $85k sold
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
NVCR: NovoCure Ltd
NVCROct 9, 2026 · close 14.58
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 46Moderate | NovoCure Ltd | $85k 6,412 shares | -3% | +34% from low-37% from high | |
| 56Moderate | NVCRbuy NovoCure Ltd | $232k 20,000 shares | +17% | 0% from low-66% from high |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 3, 2026 | NVCR NovoCure Ltd | AGrant or award Ordinary Shares | +55,137 | $0.00 | $0 | 189,254 | Mar 5, 2026 |
| Mar 4, 2026 | NVCR NovoCure Ltd | SOpen-market sale Ordinary Shares | -6,412 | $13.31 | $85k | 182,842 | Mar 5, 2026 |
| Mar 3, 2026 | NVCR NovoCure Ltd | AGrant or award Stock Option (Right to Buy)derivative | +80,674 | $0.00 | $0 | 80,674 | Mar 5, 2026 |
| Nov 4, 2025 | NVCR NovoCure Ltd | FTax withholding Ordinary Shares | -7,033 | $12.23 | $86k | 134,117 | Nov 4, 2025 |
| Jul 29, 2025 | NVCR NovoCure Ltd | POpen-market purchase Ordinary Shares | +10,000 | $11.63 | $116k | 131,150 | Jul 30, 2025 |
| Jul 29, 2025 | NVCR NovoCure Ltd | POpen-market purchase Ordinary Shares | +5,000 | $11.60 | $58k | 136,150 | Jul 30, 2025 |
| Jul 29, 2025 | NVCR NovoCure Ltd | POpen-market purchase Ordinary Shares | +5,000 | $11.50 | $58k | 141,150 | Jul 30, 2025 |
| Mar 4, 2025 | NVCR NovoCure Ltd | AGrant or award Ordinary Shares | +54,975 | $18.19 | $1000k | 121,150 | Mar 6, 2025 |
| Mar 4, 2025 | NVCR NovoCure Ltd | AGrant or award Stock Options (Right to buy)derivative | +81,499 | $18.19 | $1.5M | 81,499 | Mar 6, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.